article thumbnail

Insights into the design, development and implementation of a novel digital health tool for skilled birth attendants to support quality maternity care in Kenya

BMJ

doi: 10.1136/fmch-2020-000845 The appetite for and ability to collect accurate digital patient-level data in low-resource settings has fueled numerous massive global health initiatives. Mobile phone penetration has finally exceeded 90% in low- and middle-income countries.

article thumbnail

Caring for Patients with Duchenne Muscular Dystrophy in the Emergency Department: A Problem-Based Approach

PEMBlog

The condition affects multiple organ systems—muscular, cardiac, and respiratory—leading to a myriad of clinical complications. Once patients become non-ambulatory, they often develop secondary complications like lymphedema, which further complicates their care. 2020 Jun 5;15(1):141. Orphanet J Rare Dis.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

MyChart Messages the Wild West of Patient Communication

33 Charts

According to Epic, the number of patient messages spiked 151 percent nationally from the period covering the first 11 weeks of 2020 through the end of the year. And individual practice styles are fine. More recently health professionals have seen a rise in MyChart messages coming in through the Epic patient portal. Pretty simple.

article thumbnail

FDA Creates a New Advisory Committee for Genetic Metabolic Diseases – Could This Be an Opportunity to Support Rare Disease Product Development More Broadly?

FDA Law Blog

Janet Maynard, Director of this Office, highlighted in the press release that “[g]enetic metabolic diseases include very rare diseases that individually affect a limited number of patients. GeMDAC’s mandate is to advise the Agency on these complicated issues in this challenging area of medical product development.

article thumbnail

Mastering Responses to FDA 510(k) AI Letters: A Strategic Approach

FDA Law Blog

Performance Metric FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 Average Number of FDA Days to MDUFA IV Decision 72.62 These AI requests often address complicated scientific scenarios in which a submitter has already provided some information, but FDA is not completely satisfied. Average Number of Industry Days to MDUFA IV Decision 54.69

article thumbnail

Diabetes in Late Life: Nadine Carter, Tamryn Gray, Alex Lee

GeriPal

-@AlexSmithMD Additional Links: – Fingerstick monitoring in VA nursing homes (too common!) – Improving diabetes management in hospice – Continuous Glucose Monitoring complicating end of life care Transcript Eric: Welcome to the GeriPal podcast. This is Eric Widera. Alex Smith: This is Alex Smith. Is that your experience?

article thumbnail

Factors Associated with Accumulating Diabetes Complications in a Medicare Advantage Cohort to Inform a Prediction Tool [Diabetes and endocrine disease]

Annals of Family Medicine

Context: Complications contribute to significant type 2 diabetes mellitus (T2DM) morbidity. While preventable, many fail to receive timely treatment in primary care, leading the most vulnerable to accumulate complications. Results: We included 49,843 individuals in model 1.